Scientific development of the CNIC cardiovascular polypill: from conceptualization to clinical efficacy
Rev Esp Cardiol (Engl Ed). 2023 Dec;76(12):1055-1060.
doi: 10.1016/j.rec.2023.06.019.
Epub 2023 Oct 20.
[Article in
English,
Spanish]
Affiliations
- 1 Centro Integral de Enfermedades Cardiovasculares (CIEC), Hospital Universitario HM Montepríncipe, Grupo HM Hospitales, Madrid, Spain; Facultad HM Hospitales de Ciencias de la Salud de la Universidad Camilo José Cela, Madrid, Spain; Centro Nacional de Investigaciones Cardiovasculares (CNIC), Instituto de Salud Carlos III, Madrid, Spain.
- 2 Centro Nacional de Investigaciones Cardiovasculares (CNIC), Instituto de Salud Carlos III, Madrid, Spain; Mount Sinai Heart, The Mount Sinai Hospital, Nueva York, United States. Electronic address: valentin.fuster@mountsinai.org.
No abstract available
MeSH terms
-
Antihypertensive Agents / therapeutic use
-
Cardiovascular Agents* / therapeutic use
-
Cardiovascular Diseases* / drug therapy
-
Concept Formation
-
Drug Combinations
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
-
Medication Adherence
-
Treatment Outcome
Substances
-
Cardiovascular Agents
-
Antihypertensive Agents
-
Drug Combinations
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors